Nifty
Sensex
:
:
10763.40
35774.88
81.20 (0.76%)
317.72 (0.90%)

Pharmaceuticals & Drugs

Rating :
56/99

BSE: 500257 | NSE: LUPIN

855.50
-9.20 (-1.06%)
19-Nov-2018 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  868.00
  •  875.00
  •  851.70
  •  864.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1287405
  •  11013.75
  •  986.10
  •  723.65

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 39,048.20
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 44,782.97
  • 0.58%
  • 2.89

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 47.00%
  • 1.33%
  • 11.59%
  • FII
  • DII
  • Others
  • 0.45%
  • 11.85%
  • 27.78%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.12
  • 6.97
  • 3.50

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.59
  • 0.95
  • -3.11

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -6.87
  • -33.01
  • -52.11

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.70
  • 26.51
  • 25.60

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.88
  • 5.87
  • 4.57

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.40
  • 16.61
  • 15.64

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
3,951.06
3,951.96
-0.02%
3,855.93
3,869.58
-0.35%
4,033.83
4,253.30
-5.16%
3,975.62
4,482.87
-11.32%
Expenses
3,401.42
3,098.91
9.76%
3,328.96
3,101.21
7.34%
3,325.08
3,471.93
-4.23%
3,287.28
3,264.24
0.71%
EBITDA
549.64
853.05
-35.57%
526.97
768.37
-31.42%
708.75
781.37
-9.29%
688.34
1,218.63
-43.52%
EBIDTM
13.91%
21.59%
13.67%
19.86%
17.57%
18.37%
17.31%
27.18%
Other Income
230.68
74.04
211.56%
184.20
31.97
476.17%
144.92
45.34
219.63%
28.42
103.29
-72.49%
Interest
73.82
47.92
54.05%
68.72
43.90
56.54%
58.53
40.62
44.09%
54.00
48.44
11.48%
Depreciation
265.49
272.18
-2.46%
258.98
260.51
-0.59%
272.83
267.42
2.02%
280.35
230.91
21.41%
PBT
441.01
606.99
-27.34%
383.47
495.93
-22.68%
-942.04
518.67
-
382.41
1,042.57
-63.32%
Tax
172.91
154.06
12.24%
181.14
136.81
32.40%
-163.18
136.68
-
160.77
409.48
-60.74%
PAT
268.10
452.93
-40.81%
202.33
359.12
-43.66%
-778.86
381.99
-
221.64
633.09
-64.99%
PATM
6.79%
11.46%
5.25%
9.28%
-19.31%
8.98%
5.58%
14.12%
EPS
5.88
10.07
-41.61%
4.48
7.93
-43.51%
-17.33
8.42
-
4.91
14.02
-64.98%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
15,816.44
15,804.15
17,494.33
14,255.54
12,770.01
11,286.57
9,641.30
7,082.91
5,818.97
4,870.79
3,866.64
Net Sales Growth
-4.48%
-9.66%
22.72%
11.63%
13.14%
17.06%
36.12%
21.72%
19.47%
25.97%
 
Cost Of Goods Sold
5,592.25
4,733.76
4,660.97
4,010.21
3,806.16
3,485.50
3,221.50
2,364.87
2,060.99
1,821.29
1,604.09
Gross Profit
10,224.19
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
3,757.98
3,049.50
2,262.55
GP Margin
64.64%
70.05%
73.36%
71.87%
70.19%
69.12%
66.59%
66.61%
64.58%
62.61%
58.51%
Total Expenditure
13,342.74
12,656.64
13,001.19
10,570.19
9,150.42
8,283.78
7,371.41
5,638.20
4,641.13
3,886.90
3,127.36
Power & Fuel Cost
-
433.88
377.86
381.27
362.81
334.29
320.22
268.82
205.47
154.66
139.11
% Of Sales
-
2.75%
2.16%
2.67%
2.84%
2.96%
3.32%
3.80%
3.53%
3.18%
3.60%
Employee Cost
-
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
767.56
549.96
474.16
% Of Sales
-
18.13%
16.29%
15.02%
13.68%
12.98%
13.14%
13.69%
13.19%
11.29%
12.26%
Manufacturing Exp.
-
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
603.68
500.14
261.34
% Of Sales
-
13.21%
12.98%
12.39%
10.34%
10.01%
10.13%
10.63%
10.37%
10.27%
6.76%
General & Admin Exp.
-
1,219.96
1,306.27
1,195.98
806.87
810.53
692.06
471.23
325.19
292.37
192.75
% Of Sales
-
7.72%
7.47%
8.39%
6.32%
7.18%
7.18%
6.65%
5.59%
6.00%
4.98%
Selling & Distn. Exp.
-
1,150.61
1,252.77
870.29
835.48
775.26
709.62
647.88
547.48
446.97
354.48
% Of Sales
-
7.28%
7.16%
6.10%
6.54%
6.87%
7.36%
9.15%
9.41%
9.18%
9.17%
Miscellaneous Exp.
-
166.20
283.61
204.82
271.21
283.96
184.88
162.80
130.76
121.51
354.48
% Of Sales
-
1.05%
1.62%
1.44%
2.12%
2.52%
1.92%
2.30%
2.25%
2.49%
2.62%
EBITDA
2,473.70
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
1,177.84
983.89
739.28
EBITDA Margin
15.64%
19.92%
25.68%
25.85%
28.34%
26.60%
23.54%
20.40%
20.24%
20.20%
19.12%
Other Income
588.22
150.35
106.51
185.19
239.75
116.48
27.85
14.35
22.19
14.20
4.61
Interest
255.07
204.35
152.53
59.47
9.81
26.65
40.95
35.47
34.48
38.49
49.86
Depreciation
1,077.65
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
171.18
123.91
87.99
PBT
264.85
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
606.04
Tax
351.64
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
114.98
136.02
98.30
Tax Rate
132.77%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
11.56%
16.28%
16.22%
PAT
-86.79
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
864.55
688.51
504.88
PAT before Minority Interest
-95.96
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
879.39
699.67
507.74
Minority Interest
-9.17
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
-14.84
-11.16
-2.86
PAT Margin
-0.55%
1.57%
14.57%
15.82%
18.82%
16.27%
13.63%
12.25%
14.86%
14.14%
13.06%
PAT Growth
-104.75%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
0.36%
25.57%
36.37%
 
Unadjusted EPS
-2.06
5.56
56.69
50.25
53.54
40.99
29.39
19.43
19.36
15.84
60.84

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
3,281.08
2,567.83
1,424.82
Share Capital
90.42
90.32
90.12
89.90
89.68
89.51
89.33
89.24
88.94
82.82
Total Reserves
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
3,190.59
2,478.35
1,341.93
Non-Current Liabilities
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
533.59
1,283.35
1,339.71
Secured Loans
448.03
217.15
5.55
12.50
24.42
37.95
27.76
54.25
872.24
756.92
Unsecured Loans
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
244.91
267.61
466.35
Long Term Provisions
356.85
308.73
190.00
162.03
132.49
112.45
77.02
37.28
0.00
0.00
Current Liabilities
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
2,507.37
1,189.25
1,216.19
Trade Payables
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
993.03
883.52
710.25
Other Current Liabilities
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
201.02
82.82
323.23
Short Term Borrowings
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
791.09
0.00
0.00
Short Term Provisions
551.23
569.39
325.67
574.26
345.40
355.97
316.86
522.23
222.91
182.71
Total Liabilities
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92
3,994.97
Net Block
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
2,056.83
1,906.17
1,518.57
Gross Block
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
2,964.34
2,613.39
2,137.40
Accumulated Depreciation
2,459.58
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
907.51
707.22
618.83
Non Current Assets
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
2,869.33
2,290.47
1,764.10
Capital Work in Progress
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
478.17
348.80
222.62
Non Current Investment
26.71
22.00
14.33
2.51
2.06
2.06
2.80
3.15
26.43
21.56
Long Term Loans & Adv.
383.00
950.76
960.22
274.20
372.99
387.36
396.94
314.42
0.00
0.00
Other Non Current Assets
9.38
7.96
7.70
0.32
0.00
0.00
0.00
4.52
0.00
0.00
Current Assets
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
3,504.22
2,775.45
2,230.87
Current Investments
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
0.00
0.00
0.00
Inventories
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
1,199.96
971.49
957.16
Sundry Debtors
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
1,255.64
1,126.57
917.97
Cash & Bank
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
420.14
201.53
77.77
Other Current Assets
1,711.95
533.43
479.44
240.07
532.99
572.33
427.17
628.48
475.86
277.97
Short Term Loans & Adv.
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
515.64
475.86
277.97
Net Current Assets
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
996.85
1,586.20
1,014.68
Total Assets
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92
3,994.97

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
797.98
676.41
469.54
PBT
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
606.04
Adjustment
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
207.16
144.33
144.21
Changes in Working Capital
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
-159.56
-136.62
-173.89
Cash after chg. in Working capital
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
1,041.97
843.40
576.36
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
-243.99
-166.99
-106.82
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,407.27
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
-519.56
-680.17
-509.62
Net Fixed Assets
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
-558.11
-309.75
-223.23
Net Investments
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
43.19
-250.20
-181.38
Others
-1,564.03
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
-4.64
-120.22
-105.01
Cash from Financing Activity
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
-162.52
136.13
-167.15
Net Cash Inflow / Outflow
-1,148.18
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
115.90
132.37
-207.23
Opening Cash & Equivalents
2,799.47
780.22
2,095.06
606.62
310.93
244.65
295.88
164.22
68.08
270.66
Closing Cash & Equivalent
1,651.29
2,799.47
780.22
2,108.43
606.62
310.93
244.65
295.88
197.99
68.08

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
295.64
295.04
245.21
196.17
154.00
116.13
89.78
73.51
57.73
34.41
ROA
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
15.37%
15.44%
13.83%
ROE
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
30.08%
35.05%
37.55%
ROCE
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
25.24%
27.51%
25.57%
Fixed Asset Turnover
1.20
1.62
1.80
2.15
2.28
2.19
1.99
2.10
2.06
2.05
Receivable days
109.70
92.39
92.24
72.65
74.67
74.61
77.76
74.26
76.18
77.48
Inventory Days
84.35
72.15
73.96
65.73
65.48
69.24
75.12
67.69
71.86
81.42
Payable days
68.56
59.62
63.20
64.43
63.78
63.76
64.11
61.46
64.47
62.70
Cash Conversion Cycle
125.48
104.91
103.00
73.94
76.37
80.10
88.76
80.49
83.57
96.21
Total Debt/Equity
0.53
0.60
0.65
0.06
0.09
0.22
0.41
0.35
0.44
0.86
Interest Cover
3.66
24.18
56.89
349.10
107.25
48.00
34.72
29.84
22.71
13.15

News Update:


  • Lupin receives USFDA's approval for Decitabine for Injection
    15th Nov 2018, 11:24 AM

    Decitabine for Injection, 50 mg/vial, Single-Dose Vial had annual sales of approximately $135.9 million in the US

    Read More
  • Lupin receives USFDA approval for Budesonide Inhalation Suspension
    13th Nov 2018, 11:47 AM

    Budesonide Inhalation Suspension, 0.5 mg/2 mLSingle-DoseAmpules had annual sales of approximately $474.5 million in the US

    Read More
  • Lupin launches generic Atovaquone Oral Suspension USP in US
    12th Nov 2018, 16:00 PM

    It is indicated for the prevention of Pneumocystis jirovecii pneuomonia in adults and adolescents aged 13 years and older

    Read More
  • Lupin's Nagpur facility receives EIR from USFDA
    12th Nov 2018, 09:53 AM

    The inspection conducted in September 2018 concluded without any observations

    Read More
  • Lupin’s US arm recalls 6,752 bottles of Testosterone Topical solution from US
    6th Nov 2018, 16:17 PM

    The reason for recall is Defective Container Repetitive complaints received indicating pump not working

    Read More
  • Lupin receives FDA approval for Doxercalciferol Injection
    5th Nov 2018, 16:28 PM

    Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vial is the generic version of Genzyme's Hectorol Injection

    Read More
  • Lupin reports 42% fall in Q2 consolidated net profit
    2nd Nov 2018, 11:46 AM

    Total income of the company increased by 3.87% at Rs 4,181.74 crore for Q2FY19

    Read More
  • Lupin - Quarterly Results
    31st Oct 2018, 14:43 PM

    Read More
  • Lupin receives USFDA’s approval for generic Triamcinolone Acetonide Ointment
    22nd Oct 2018, 16:19 PM

    It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses

    Read More
  • Lupin Neurosciences receives positive CHMP opinion for NaMuscla
    20th Oct 2018, 09:25 AM

    It is for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders

    Read More
  • USFDA completes inspection at Lupin’s Indore facility
    19th Oct 2018, 16:00 PM

    The inspection was a GMP inspection for the facility and also a Pre-Approval Inspection (PAI) for the company's Tiotropium DPI ANDA

    Read More
  • Lupin’s arm partners with ASHA, NPWH
    16th Oct 2018, 11:41 AM

    Lupin Pharmaceuticals has entered into partnership to conduct a two-pronged national online survey among women

    Read More
  • Lupin receives tentative approval from USFDA for generic Lurasidone Hydrochloride Tablets
    15th Oct 2018, 14:22 PM

    Lurasidone Hydrochloride Tablets had annual sales of around $3116 million in the US

    Read More
  • Lupin launches generic Clobetasol Propionate Ointment in US
    9th Oct 2018, 15:24 PM

    Clobetasol Propionate Ointment USP 0.05% had annual sales of around $93.4 million in the US

    Read More
  • Lupin launches generic Potassium Chloride Oral Solution
    4th Oct 2018, 16:33 PM

    The company’s Potassium Chloride Oral Solution is the generic equivalent of Genus Lifesciences, Inc.'s Potassium Chloride Oral Solution

    Read More
  • Lupin, Lilly partner for improved access to diabetes treatment in India
    1st Oct 2018, 11:18 AM

    Lupin will distribute and market Lilly’s Aplevant (dulaglutide), a once-weekly injection for type 2 diabetes treatment

    Read More
  • USFDA completes inspection at Lupin’s Nagpur facility
    14th Sep 2018, 10:42 AM

    This inspection was a product specific pre-approval inspection

    Read More
  • Lupin gets approval from USFDA for Atovaquone Oral Suspension
    12th Sep 2018, 15:53 PM

    Atovaquone Oral Suspension, 750 mg/5 mL had annual sales of around $117.4 million in the US

    Read More
  • Lupin expecting to train 1,000 graduates for pharma industry
    7th Sep 2018, 11:27 AM

    The company is expecting to train more than 1,000 under graduates under its Learn and Earn Initiative

    Read More
  • USFDA completes inspection at Lupin’s Tarapur facility
    4th Sep 2018, 11:02 AM

    The inspection closed with one observation, a procedural deficiency

    Read More
  • Lupin gets USFDA's approval for generic Potassium Chloride Oral Solution USP
    31st Aug 2018, 15:28 PM

    Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%) had annual sales of approximately $184.95 million in the US

    Read More
  • Lupin receives USFDA's approval for generic Gabapentin Tablets
    28th Aug 2018, 12:25 PM

    Gabapentin Tablets USP, 600 mg and 800 mg had annual sales of around $180.7 million in the US

    Read More
  • Lupin launches four tablets
    27th Aug 2018, 12:40 PM

    Lupin's Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, are the generic equivalent of Bayer's Beyaz Tablets

    Read More
  • Lupin gets EIR from USFDA for inspection of its Nagpur facility
    24th Aug 2018, 14:17 PM

    The inspection was conducted in May 2018

    Read More
  • Lupin enters into prescription dermatology segment in Brazil
    23rd Aug 2018, 11:41 AM

    The company has entered into the said segment with the launch of Fillerina and Recrexina under the Lupin High-End Skin Science umbrella

    Read More
  • Lupin's US arm recalling 11,706 bottles of hypertension drug in US
    23rd Aug 2018, 11:10 AM

    The reason of the recall is ‘presence of foreign substance: Product complaint was received of metal contaminant observed in one tablet'

    Read More
  • Lupin receives tentative USFDA approval for generic Nudovra
    22nd Aug 2018, 15:37 PM

    Nudovra tablets had annual sales of around $31.4 million in the US

    Read More
  • Lupin launches generic Clobetasol Propionate Cream in US
    21st Aug 2018, 15:13 PM

    Clobetasol Propionate Cream USP 0.05% had annual sales of around $108.6 million in the US

    Read More
  • Lupin receives USFDA's approval for generic Hydrocortisone Butyrate Lotion
    21st Aug 2018, 10:43 AM

    Hydrocortisone Butyrate Lotion, 0.1% had annual sales of approximately $13.8million in the US

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.